SciELO - Scientific Electronic Library Online

 
vol.142 número5Asociación del nivel socioeconómico con la higiene bucal en preescolares bajo el programa de odontología preventiva del IMSS en CampecheEsporotricosis en algunas comunidades rurales de la Sierra Norte de Puebla: Informe de 55 casos (Septiembre 1995 - Diciembre 2005) índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Gaceta médica de México

versão impressa ISSN 0016-3813

Resumo

CARRILLO-ESPER, Raúl et al. Recombinant factor VII activated in non-hemophiliac patients with acute severe hemorrhage in the intensive care unit. Gac. Méd. Méx [online]. 2006, vol.142, n.5, pp. 369-376. ISSN 0016-3813.

Background. Severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. Recombinant Factor VIIa (rFVIIa) constitutes a new therapeutic alternative. Objective. Analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rFVIIa. Material and Methods. Ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rFVIIa. We used a t test for statistic analyses. Significance was set at p < 0.001. Results. Among patients treated with rFVIIa, hemorrhage was controlled and the use of blood products was significantly diminished (p < 0.001). Coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p < 0.001). Conclusions. rFVIIa is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.

Palavras-chave : Recombinant Factor VIIa; severe hemorrhage; coagulation cell model.

        · resumo em Espanhol     · texto em Espanhol     · pdf em Espanhol